When treated with a relatively low dose of RP116 (MOI of 10) and IL-18/-21-pretreated eNK cells (E:T ratio of 0.25:1), the combination treatment showed the lowest number of viable cancer cells in both cell lines (Fig. 5A). Here, IL18 is linked to cancer.